PT-141 (bremelanotide) is an FDA-approved peptide therapy for premenopausal women with hypoactive sexual desire disorder (HSDD). It works by activating melanocortin receptors in the brain, enhancing sexual desire and reducing associated distress. Research also indicates potential benefits for men with erectile dysfunction, especially those unresponsive to traditional treatments.
22 in stock
Clinically proven to increase sexual desire in women with HSDD
Reduces distress related to low libido
Potential alternative for men with erectile dysfunction
Acts on central nervous system pathways, differing from blood flow-based treatments
All products offered on this website are strictly intended for research and development purposes only. They are not for human consumption in any form.
The statements presented on this website have not been evaluated by the U.S. Food and Drug Administration (FDA). Neither the statements nor the products offered by this company are intended to diagnose, treat, cure, or prevent any disease.
Superhuman Peptides operates solely as a chemical supplier. It is not a compounding pharmacy or a chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act. Superhuman Peptides is also not an outsourcing facility as defined under Section 503B of the same Act.
This website contains information about supplementary products. By entering, you confirm that you are of legal age (18 years or older) to access this information. If you are not of legal age, please leave this site immediately.
